fbpx Skip to main content

Collaboration between US Oncology Research, The US Oncology Network (The Network), and Ontada™ from McKesson resulted in more than 30 studies being submitted by the group for the 63rd American Society of Hematology (ASH) Annual Meeting and Exposition. The studies delve into various areas of blood disorders and related treatments, including different types of lymphomas and hematological adverse event management. 

In a press release prior to ASH, McKesson outlined some of the significant studies it will be part of presenting. One such presentation will be an oral presentation of the safety and efficacy of a new regimen for patients with relapsed/refractory (R/R) diffuse large B cell lymphoma (DLBCL) who cannot receive autologous stem cell transplant (Abstract 527).

Dr. John Burke of Rocky Mountain Cancer Centers will be presenting the study’s results, sharing the encouraging results uncovered related to tolerability and efficacy of a new specific treatment regimen for patients with R/R DLBCL. 

There will also be a poster presentation at ASH focused on the treatment patterns and other factors connected to adverse hematological side effects experienced by patients with extensive stage small cell lung cancer (ES-SCLC) during treatment (Abstract 1913).

Led by Dr. Jerome Goldschmidt of Blue Ridge Cancer Center, the study investigated the healthcare resource utilization by these patients when there are hematological adverse events, such as dose reductions and treatment delays, as well as the costs endured by patients related to their care. The study’s results support the need for more research into healthcare resource utilization and costs for patients in order to fully understand the management of hematological adverse events. 

Dr. Robert L. Coleman, the chief scientific officer of US Oncology Research, voiced in the press release their excitement for not only coming back together with the hematology community in person and virtually but also sharing their new data on treating blood cancers that are typically hard to treat [1].

You May Also Like::  Stemness in Leukemia

Source:

[1] US Oncology Research, The US Oncology Network and Ontada announce data presentations across areas of critical need at 2021 American Society of Hematology Annual Meeting and Exposition | McKesson. (2021, December 9). [Press release]. https://www.mckesson.com/About-McKesson/Newsroom/Press-Releases/2021/USON-Ontada-Announce-Data-Presentations-Across-Areas-Critical-Need/

Share this article